Next Article in Journal
Epidermal Growth Factor Pathway Signaling in Drosophila Embryogenesis: Tools for Understanding Cancer
Next Article in Special Issue
Immunotherapy for Colorectal Cancer
Previous Article in Journal
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
Previous Article in Special Issue
Advances in Cancer Immunotherapy in Solid Tumors
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Cancers 2017, 9(2), 15; doi:10.3390/cancers9020015

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions

1
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
2
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 14 December 2016 / Accepted: 18 January 2017 / Published: 27 January 2017
(This article belongs to the Special Issue Cancer Immunotherapies)
View Full-Text   |   Download PDF [561 KB, uploaded 4 February 2017]   |  

Abstract

Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens. This represents a significant milestone in this disease after a void of over 30 years. In addition to atezolizumab, a variety of checkpoint inhibitors have shown a significant activity in advanced/metastatic urothelial carcinoma and are expected to gain Food and Drug Administration (FDA) approval in the near future. The introduction of novel immunotherapy agents has led to rapid changes in the field of urothelial carcinoma. Numerous checkpoint inhibitors are being tested alone or in combination in the first and subsequent-line therapies of metastatic disease, as well as neoadjuvant and adjuvant settings. They are also being studied in combination with radiation therapy and for non-muscle invasive bladder cancer refractory to BCG. Furthermore, immunotherapy is being utilized for those ineligible for firstline platinum-based chemotherapy. This review outlines the novel immunotherapy agents which have either been approved, or are currently being investigated in clinical trials in UC. View Full-Text
Keywords: urothelial carcinoma; bladder cancer; immunotherap urothelial carcinoma; bladder cancer; immunotherap
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gupta, S.; Gill, D.; Poole, A.; Agarwal, N. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers 2017, 9, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top